| Paper |
Title |
Page |
| TUPAN117 |
Progress on Dual Harmonic Acceleration on the ISIS Synchrotron
|
1649 |
| |
- A. Seville
- D. J. Adams, C. W. Appelbee, D. Bayley, N. E. Farthing, I. S.K. Gardner, M. G. Glover, B. G. Pine, J. W.G. Thomason, C. M. Warsop
STFC/RAL/ISIS, Chilton, Didcot, Oxon
|
|
| |
The ISIS facility at the Rutherford Appleton Laboratory in the UK is currently the most intense pulsed, spallation, neutron source. The accelerator consists of a 70 MeV H- linac and an 800 MeV, 50 Hz, rapid cycling, proton synchrotron. The synchrotron beam intensity is 2.5·1013 protons per pulse, corresponding to a mean current of 200 μA. The synchrotron beam is accelerated using six, ferrite loaded, RF cavities with harmonic number 2. Four additional, harmonic number 4, cavities have been installed to increase the beam bunching factor with the potential of raising the operating current to 300μA. The dual harmonic system has now been used operationally for the first time, running reliably throughout the last ISIS user cycle of 2006. This paper reports on the hardware commissioning, beam tests and improved operational results obtained so far with dual harmonic acceleration.
|
|
| THPMN076 |
PAMELA - A Model for an FFAG based Hadron Therapy Machine
|
2880 |
| |
- J. K. Pozimski
- R. J. Barlow
UMAN, Manchester
- J. Cobb, T. Yokoi
OXFORDphysics, Oxford, Oxon
- B. Cywinski
University of Leeds, Leeds
- T. R. Edgecock
STFC/RAL, Chilton, Didcot, Oxon
- A. Elliott
Beatson Institute for Cancer Research, Glasgow
- M. Folkard, B. Vojnovic
Gray Cancer Institute, Northwood, Middlesex
- I. S.K. Gardner
STFC/RAL/ISIS, Chilton, Didcot, Oxon
- B. Jones
University Hospital Birmingham, Edgbaston, Birmingham
- K. Kirkby, R. Webb
UOSIBS, Guildford
- G. McKenna
University of Oxford, Oxford
- K. J. Peach
JAI, Oxford
- M. W. Poole
STFC/DL/ASTeC, Daresbury, Warrington, Cheshire
|
|
| |
Approximately one third of the world?s 15000 accelerators are used for tumour therapy and other medical applications. Most of these are room temperature cyclotrons: a few are synchrotrons. Neither of these have ideal characteristics for a dedicated medical accelerator. The characteristics of FFAGs make them ideally suited to such applications, as the much smaller magnet size, greater compactness and variable energy offers considerable cost and operational benefits especially in a hospital setting. In the first stage the work on PAMELA will focus on the optimization of the FFAG design to deliver the specific machine parameters demanded by therapy applications. In this phase of the PAMELA project the effort will concentrate on the design of a semi-scaling type FFAGs to deliver a 450 MeV/u carbon ion beam, including detailed lattice and tracking studies. The second stage will use the existing expertise in the BASROC consortium to undertake a design of the magnets and RF system for PAMELA. An outline of the overall concept of PAMELA will be discussed and the actual status of the work will be presented.
|
|